Clearmind briefs FDA panel at Washington psychedelic drugs hearing
CMND•Clearmind testifies at FDA psychedelic hearing
Clearmind Medicine testified at the FDA’s psychedelic hearing in Washington on Sept. 14, 2026, following an FDA invitation.
Mary-Elizabeth Gifford urged broader patient access, citing trial findings at Yale and Johns Hopkins on non-hallucinogenic neuroplastogens.
Gifford said eliminating supervised dosing could support scalable treatment through existing primary care and VA systems.
MEAI, Clearmind’s alcohol use disorder candidate, is in an FDA-authorized Phase 2a trial at Yale and Johns Hopkins.
